BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28731711)

  • 1. Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma.
    Codreanu SG; Hoeksema MD; Slebos RJC; Zimmerman LJ; Rahman SMJ; Li M; Chen SC; Chen H; Eisenberg R; Liebler DC; Massion PP
    J Proteome Res; 2017 Sep; 16(9):3266-3276. PubMed ID: 28731711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers.
    Kikuchi T; Hassanein M; Amann JM; Liu Q; Slebos RJ; Rahman SM; Kaufman JM; Zhang X; Hoeksema MD; Harris BK; Li M; Shyr Y; Gonzalez AL; Zimmerman LJ; Liebler DC; Massion PP; Carbone DP
    Mol Cell Proteomics; 2012 Oct; 11(10):916-32. PubMed ID: 22761400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum proteomic patterns may assist the diagnosis of solitary pulmonary nodules].
    Luo XY; Chen HQ; Sun YH; Zhou JH; Wang WF; Liao P; Xiang CQ
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):907-10. PubMed ID: 17533741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early detection of lung cancer by molecular markers in endobronchial epithelial-lining fluid.
    Kahn N; Meister M; Eberhardt R; Muley T; Schnabel PA; Bender C; Johannes M; Keitel D; Sültmann H; Herth FJ; Kuner R
    J Thorac Oncol; 2012 Jun; 7(6):1001-8. PubMed ID: 22588153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics-based identification of tumor relevant proteins in lung adenocarcinoma.
    Zhou X; Xue L; Hao L; Liu S; Zhou F; Xiong H; Qi X; Lin D; Shao S
    Biomed Pharmacother; 2013 Sep; 67(7):621-7. PubMed ID: 23916545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-144 regulates proliferation, invasion, and apoptosis of cells in malignant solitary pulmonary nodule via zinc finger E-box-binding homeobox 1.
    Zhang G; An H; Fang X
    Int J Clin Exp Pathol; 2015; 8(5):5960-7. PubMed ID: 26191328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Omics technologies in diagnostics of lung adenocarcinoma].
    Novikova SE; Kurbatov LK; Zavialova MG; Zgoda VG; Archakov AI
    Biomed Khim; 2017 May; 63(3):181-210. PubMed ID: 28781253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6.
    Han HS; Son SM; Yun J; Jo YN; Lee OJ
    FEBS Lett; 2014 Oct; 588(20):3744-50. PubMed ID: 25171863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of proteins expressed differently among surgically resected stage I lung adenocarcinomas.
    Ha ES; Choi S; In KH; Lee SH; Lee EJ; Lee SY; Kim JH; Shin C; Shim JJ; Kang KH; Phark S; Sul D
    Clin Biochem; 2013 Mar; 46(4-5):369-77. PubMed ID: 23200884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction.
    Ortea I; Rodríguez-Ariza A; Chicano-Gálvez E; Arenas Vacas MS; Jurado Gámez B
    J Proteomics; 2016 Apr; 138():106-14. PubMed ID: 26917472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
    Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J
    J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.
    Fahrmann JF; Grapov D; DeFelice BC; Taylor S; Kim K; Kelly K; Wikoff WR; Pass H; Rom WN; Fiehn O; Miyamoto S
    Cancer Biomark; 2016 Mar; 16(4):609-17. PubMed ID: 27002763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear localization of B7-H4 in pulmonary adenocarcinomas presenting as a solitary pulmonary nodule.
    Chen C; Zhu WD; Xie F; Huang JA
    Oncotarget; 2016 Sep; 7(36):58563-58568. PubMed ID: 27438152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of exhaled carbonyl compounds distinguishes benign from malignant pulmonary disease.
    Bousamra M; Schumer E; Li M; Knipp RJ; Nantz MH; van Berkel V; Fu XA
    J Thorac Cardiovasc Surg; 2014 Sep; 148(3):1074-80; discussion 1080-1. PubMed ID: 25129599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clincopathological variables to differentiate the nature of isolated pulmonary nodules in patients who received curative surgery for colorectal cancer.
    Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Ma CJ; Wang JY
    Asian J Surg; 2019 Feb; 42(2):425-432. PubMed ID: 30262438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules.
    Xing L; Su J; Guarnera MA; Zhang H; Cai L; Zhou R; Stass SA; Jiang F
    Clin Cancer Res; 2015 Jan; 21(2):484-9. PubMed ID: 25593345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
    Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated quantitative proteomic and transcriptomic analysis of lung tumor and control tissue: a lung cancer showcase.
    Tenzer S; Leidinger P; Backes C; Huwer H; Hildebrandt A; Lenhof HP; Wesse T; Franke A; Meese E; Keller A
    Oncotarget; 2016 Mar; 7(12):14857-70. PubMed ID: 26930711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis.
    Zhang PF; Zeng GQ; Hu R; Li C; Yi H; Li MY; Li XH; Qu JQ; Wan XX; He QY; Li JH; Chen Y; Ye X; Li JY; Wang YY; Feng XP; Xiao ZQ
    J Proteomics; 2012 Dec; 77():202-14. PubMed ID: 22982323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.